Godavari Drugs Yönetim

Yönetim kriter kontrolleri 3/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Mukund Kakani

İcra Kurulu Başkanı

₹1.8m

Toplam tazminat

CEO maaş yüzdesi	100.0%
CEO görev süresi	no data
CEO sahipliği	20.0%
Yönetim ortalama görev süresi	Veri yok
Yönetim Kurulu ortalama görev süresi	11.1yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Mukund Kakani'un ücretlendirmesi Godavari Drugs'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	₹64m
Mar 31 2024	₹2m	₹2m	₹55m
Dec 31 2023	n/a	n/a	₹42m
Sep 30 2023	n/a	n/a	₹37m
Jun 30 2023	n/a	n/a	₹37m
Mar 31 2023	₹2m	₹2m	₹38m
Dec 31 2022	n/a	n/a	₹37m
Sep 30 2022	n/a	n/a	₹44m
Jun 30 2022	n/a	n/a	₹47m
Mar 31 2022	₹1m	₹1m	₹52m
Dec 31 2021	n/a	n/a	₹53m
Sep 30 2021	n/a	n/a	₹49m
Jun 30 2021	n/a	n/a	₹47m
Mar 31 2021	₹1m	₹1m	₹41m
Dec 31 2020	n/a	n/a	₹36m
Sep 30 2020	n/a	n/a	₹31m
Jun 30 2020	n/a	n/a	₹24m
Mar 31 2020	₹1m	₹1m	₹20m
Dec 31 2019	n/a	n/a	₹16m
Sep 30 2019	n/a	n/a	₹15m
Jun 30 2019	n/a	n/a	₹15m
Mar 31 2019	₹1m	₹1m	₹12m
Dec 31 2018	n/a	n/a	₹12m
Sep 30 2018	n/a	n/a	₹10m
Jun 30 2018	n/a	n/a	₹9m
Mar 31 2018	₹1m	₹1m	₹8m

Tazminat ve Piyasa: Mukund 'nin toplam tazminatı ($USD 21.34K ), Indian pazarındaki benzer büyüklükteki şirketler için ortalamanın altındadır ($USD 42.70K ).

Tazminat ve Kazançlar: Mukund 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Mukund Kakani (72 yo)

no data

Görev süresi

₹1,800,000

Tazminat

Mr. Mukund Kakani serves as the Chief Executive Officer, Managing Director and Director of Godavari Drugs Ltd. He is a chemical engineer (B.Tech) from Osmania University.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Mukund Kakani	CEO, MD & Executive Director	no data	₹1.80m	19.99% ₹ 184.4m
Mohit Jaju	CFO & Whole Time Director	12.5yrs	₹1.80m	7.1% ₹ 65.5m
Syed Hussain	Non-Executive Independent Director	18.9yrs	₹80.00k	Veri yok
Ghanshyam Jaju	Chairman	18.2yrs	Veri yok	16.76% ₹ 154.6m
Vimala Madon	Non-Executive Independent Director	9.7yrs	₹80.00k	Veri yok
Mahendra Bhalerao	Non-Executive Independent Director	2yrs	₹80.00k	0.020% ₹ 183.8k
Dinesh Udpa	Non-Executive Independent Director	less than a year	Veri yok	Veri yok

11.1yrs

Ortalama Görev Süresi

72yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 530317 'in yönetim kurulu deneyimli ve tecrübelidir (ortalama görev süresi 11.1 yıldır).

Godavari Drugs Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

Godavari Drugs Limited, Annual General Meeting, Aug 29, 2024

Godavari Drugs Limited Announces Resignation of Ramesh Babu Telugu from the Post of Independent Director

Godavari Drugs Limited, Annual General Meeting, Aug 12, 2023

Godavari Drugs Limited Approves the Appointment of Mr. Venkatesh Achanta as Company Secretary

Godavari Drugs Limited Announces Resignation of Mrs. Rashmi Agarwal as Company Secretary and Compliance Officer

Insider recently sold ₹4.4m worth of stock

Recent updates

Investor sentiment improves as stock rises 25%

First quarter 2025 earnings released: EPS: ₹2.17 (vs ₹1.08 in 1Q 2024)

Godavari Drugs Limited to Report Q1, 2025 Results on Aug 14, 2024

Full year 2024 earnings released: EPS: ₹7.37 (vs ₹5.03 in FY 2023)

Godavari Drugs Limited, Annual General Meeting, Aug 29, 2024

Godavari Drugs Limited to Report Q4, 2024 Results on May 30, 2024

Godavari Drugs Limited to Report Q4, 2024 Results on May 30, 2024

Third quarter 2024 earnings released: EPS: ₹1.62 (vs ₹0.89 in 3Q 2023)

Godavari Drugs Limited to Report Q3, 2024 Results on Feb 13, 2024

Godavari Drugs Limited to Report Q3, 2024 Results on Feb 14, 2024

Second quarter 2024 earnings released: EPS: ₹1.14 (vs ₹1.15 in 2Q 2023)

Investor sentiment improves as stock rises 17%

Godavari Drugs Limited Announces Resignation of Ramesh Babu Telugu from the Post of Independent Director

Godavari Drugs Limited to Report Q1, 2024 Results on Aug 11, 2023

Godavari Drugs Limited, Annual General Meeting, Aug 12, 2023

Full year 2023 earnings released: EPS: ₹5.03 (vs ₹6.97 in FY 2022)

Investor sentiment improves as stock rises 20%

Godavari Drugs Limited Approves the Appointment of Mr. Venkatesh Achanta as Company Secretary

Godavari Drugs Limited to Report Q4, 2023 Results on May 29, 2023

Third quarter 2023 earnings released: EPS: ₹0.89 (vs ₹1.77 in 3Q 2022)

Godavari Drugs Limited Announces Resignation of Mrs. Rashmi Agarwal as Company Secretary and Compliance Officer

Godavari Drugs Limited to Report Q3, 2023 Results on Feb 14, 2023

Insider recently sold ₹4.4m worth of stock

Godavari Drugs Limited Appoints Mahendra Uday Bhalerao as Non-Executive Independent Director

Investor sentiment improved over the past week

Insider recently sold ₹499k worth of stock

Insufficient new directors

Godavari Drugs Limited Approves the Appointment of Mahindra Uday Bhalerao as Additional Independent Director

Godavari Drugs Limited Announces Resignation of Mr. Dilip Keshavlal Patel from Post of Non-Executive Independent Director

Godavari Drugs Limited to Report Q2, 2023 Results on Nov 12, 2022

Insider recently sold ₹395k worth of stock

First quarter 2023 earnings released: EPS: ₹1.22 (vs ₹1.89 in 1Q 2022)

Godavari Drugs Limited to Report Q1, 2023 Results on Aug 13, 2022

Investor sentiment deteriorated over the past week

Insufficient new directors

Godavari Drugs Limited Announces Resignation of Kirti Kumar Jain from the CFO

Full year 2022 earnings released: EPS: ₹6.97 (vs ₹5.48 in FY 2021)

Godavari Drugs Limited to Report Q4, 2022 Results on Apr 19, 2022

Investor sentiment improved over the past week

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Godavari Drugs Limited to Report Q3, 2022 Results on Feb 14, 2022

Investor sentiment improved over the past week

Full year 2021 earnings released: EPS ₹5.48 (vs ₹2.66 in FY 2020)

Investor sentiment improved over the past week

Full year 2021 earnings released: EPS ₹5.48 (vs ₹2.66 in FY 2020)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

New 90-day high: ₹48.10

Third quarter 2021 earnings released: EPS ₹1.33 (vs ₹0.72 in 3Q 2020)

Godavari Drugs Limited to Report Q3, 2021 Results on Feb 12, 2021

New 90-day high: ₹45.90

Investor sentiment improved over the past week

First quarter earnings released

Godavari Drugs Limited to Report Q1, 2021 Results on Aug 13, 2020

New 90-day high - ₹38.25

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş